Kernder, A. L., Filla, T., Friedrich, R., Blank, N., Ernst, D., Henes, J. C., . . . Vordenbäumen, S. (2025). First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: A multicentre, retrospective, propensity weighted cohort study. The lancet. Rheumatology, 7(6), . https://doi.org/10.1016/S2665-9913(25)00023-2
Chicago-Zitierstil (17. Ausg.)Kernder, Anna Luise, et al. "First-line Biological Versus Conventional Synthetic Disease-modifying Antirheumatic Drug Therapy in Adult-onset Still's Disease: A Multicentre, Retrospective, Propensity Weighted Cohort Study." The Lancet. Rheumatology 7, no. 6 (2025). https://doi.org/10.1016/S2665-9913(25)00023-2.
MLA-Zitierstil (9. Ausg.)Kernder, Anna Luise, et al. "First-line Biological Versus Conventional Synthetic Disease-modifying Antirheumatic Drug Therapy in Adult-onset Still's Disease: A Multicentre, Retrospective, Propensity Weighted Cohort Study." The Lancet. Rheumatology, vol. 7, no. 6, 2025, https://doi.org/10.1016/S2665-9913(25)00023-2.